NCT05099133View on ClinicalTrials.gov

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

June 28, 2022

Study Completion Date

June 28, 2022

Conditions
Atopic Dermatitis
Interventions
DRUG

LEO 138559

LEO 138559 is an antibody given by injection just under the skin.

DRUG

LEO 138559 Placebo

LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except the medical ingredient LEO 138559.

Trial Locations (1)

91206

LEO Investigational Site, Los Angeles

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY